Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.

Journal: Pharmaceutical medicine
Published Date: Apr 1, 2019

Abstract

INTRODUCTION: Pharmacovigilance (PV) detects, assesses, and prevents adverse events (AEs) and other drug-related problems by collecting, evaluating, and acting upon AEs. The volume of individual case safety reports (ICSRs) increases yearly, but it is estimated that more than 90% of AEs go unreported. In this landscape, embracing assistive technologies at scale becomes necessary to obtain a higher yield of AEs, to maintain compliance, and transform the PV professional work life.

Authors

  • Ruta Mockute
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA. Rmockute@celgene.com.
  • Sameen Desai
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
  • Sujan Perera
    Kno.e.sis Center, Wright State University, Dayton, Ohio, USA.
  • Bruno Assuncao
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
  • Karolina Danysz
    Celgene Corporation, Boudry, Switzerland.
  • Niki Tetarenko
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
  • Darpan Gaddam
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
  • Danielle Abatemarco
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
  • Mark Widdowson
    Celgene Corporation, Stockley Park, UK.
  • Sheryl Beauchamp
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
  • Salvatore Cicirello
    Celgene Corporation, Boudry, Switzerland.
  • Edward Mingle
    Celgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Keywords

External Resources

Popular Topics
Recent Journals